Incretin hormones in the treatment of type 2 diabetes

Formulary

Volumn 41, Issue 3, 2006, Pages 130-141

  Trujillo, Jennifer ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 AMINO 1 [5,6,7,8 TETRAHYDRO 3 (TRIFLUOROMETHYL) 1,2,4 TRIAZOLO[4,3 A]PYRAZIN 7 YL] 4 (2,4,5 TRIFLUOROPHENYL) 1 BUTANONE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CJC 1131; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; NEW DRUG; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN;

DIABETES MELLITUS; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 33645576200     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. American Diabetes Association. National Diabetes Fact Sheet. Available at http://www. diabetes.org/diabetes-statistics/national-diabetes-fact-sheet.jsp. Accessed February 27, 2006.
2. Ward WK, Beard JC, Halter JB, et al. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care. 1984;7:491-502.
3. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28:S4-S36.
5. UKPDS Group. Overview of 6 years' therapy of type 2 diabetes; a progressive disease (UKPDS 16). Diabetes. 1995;44:1249-1258.
6. Perley M, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954-1962.
7. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-2940.
8. Holst JJ, Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes. 2004;53 (suppl 3):S197-S204.
9. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-3723.
10. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
11. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone response, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239-1246.
12. Deacon CF. Therapeutic strategies based on glucagons-like peptide 1. Diabetes. 2004;53:2181-2189.
13. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of a 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-830.
14. Gryskiewicz KA, Coleman CI. Exenatide: a novel incretin mimetic hormone for the treatment of type 2 diabetes. Formulary. 2005;40:86-90.
15. Edward CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol. 2001;281:E155-E161.
16. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4; studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999;48:1026-1034.
17. Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagons-like peptide-1 in vivo and in vitro. Metabolism. 2001;50:S83-589.
18. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87:1282-1290.
19. Gedulin B, Jodka C, Hoyt J. Exendin-4 (AC2993) decreased glucagons secretion during hyperglycemic clamps in diabetic fatty Zucker rats (abstract). Diabetes. 1999;48 (suppl 1):A199.
20. Jodka C, Gedulin B,Young A. Exendin-4 potentially regulates gastric emptying in rats (abstract). Diabetes. 1998;47 (suppl 1):A403.
21. Fehse FC, Trautmann ME, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991-5997.
22. Byetta [package insert]. San Diego, Calif: Amylin Pharmaceuticals, Inc; 2005.
23. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26:2370-2377.
24. Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
25. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
26. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
27. 1c and weight over 82 weeks in overweight patients with type 2 diabetes (abstract). Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 477-P.
28. 1c and body weight in long-term trials are not explained by gastrointestinal side effects (abstract). Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 485-P.
29. Heine RJ, Van Gall LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143:559-569.
30. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagons-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187-1194.
31. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety, and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202.
32. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51:424-429.
33. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care. 2004;1335-1342.
34. Giannoukakis N. CJC-1131. ConjuChem. Curr Opin Invest Drugs. 2003;4:1245-1249.
35. Ratner RE, Guivarc PH, Dreyfus JF, et al. Effects of DAC-GLP:1 (CJC-1131) on glycemic control and weight over 12 weeks in metformin-treated patients with type 2 diabetes (abstract). Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 10-OR.
36. Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor LAF237 improves glycemic control in patients with type 2 diabetes (T2DM) (abstract). Presented at: American Diabetes Association 64th Annual Scientific Sessions; June 4-8, 2004. Orlando, Fla. Abstract 355-OR.
37. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.
38. Scott R, Herman G, Zhao P, et al. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D). Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 41-OR.
39. Herman G, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 541-P.
40. Brazg R, Thomas K, Zhao P, et al. Effect of adding MK-0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin. Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 11-OR.
41. First DataBank. Available at: http://www.first databank.com/. Accessed February 22, 2006.
42. DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. 2005; New York: McGraw-Hill Companies, Inc.